Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to United Therapeutics Corporation (NASDAQ: UTHR) filings with the U.S. Securities and Exchange Commission, along with AI-generated summaries to help interpret key disclosures. United Therapeutics is a biotechnology and pharmaceutical company whose common stock trades on the Nasdaq Global Select Market, as noted in its Form 8-K reports. The company develops therapies for pulmonary arterial hypertension and related lung diseases and pursues technologies to expand the availability of transplantable organs as part of its public benefit corporation mandate.
In these SEC filings, investors can review current reports on Form 8-K that describe material events such as quarterly earnings releases, clinical milestones, share repurchase arrangements, and shareholder meeting outcomes. For example, United Therapeutics has filed 8-Ks to furnish press releases on quarterly financial results, to report positive TETON-2 clinical data for nebulized Tyvaso in idiopathic pulmonary fibrosis, and to disclose accelerated share repurchase agreements under a board-authorized share repurchase program.
Filings also document corporate governance and compensation matters, including amendments and restatements of the company’s stock incentive plan, vote results from the annual meeting of shareholders, and the listing of common stock on the Nasdaq Global Select Market under the symbol UTHR. These documents provide insight into equity compensation structures, director elections, advisory votes on executive pay, and auditor ratification.
Through this page, you can quickly locate United Therapeutics’ 8-Ks and, where available, other forms such as 10-K annual reports, 10-Q quarterly reports, and Forms 3, 4, and 5 related to insider ownership and transactions. AI-powered summaries highlight the main points of lengthy filings, explain complex sections in simpler language, and draw attention to items that often matter to investors, such as revenue drivers, capital return actions, and significant clinical or regulatory updates. Real-time updates from EDGAR ensure that new UTHR filings appear promptly, helping users monitor the company’s regulatory and disclosure record in one place.
United Therapeutics Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at a strike price of $146.03 per share, then sold 9,500 shares in multiple open-market trades around $531–$541 on March 17, 2026.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After these trades, she holds 40,513 shares directly, plus additional indirect holdings through her spouse and family trusts, including 324,518 shares held by a trust.
United Therapeutics Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. She exercised stock options for 9,500 shares of common stock at an exercise price of
On the same date, she sold 9,500 common shares in a series of open-market trades at prices ranging from
UNITED THERAPEUTICS Corp President and COO Michael Benkowitz reported routine equity compensation activity involving restricted stock units and common shares. On March 15, 2026, a trust associated with him exercised restricted stock units that each convert into one share of common stock, resulting in 33,382 shares of common stock held indirectly by the trust.
Of these shares, 14,706 shares of common stock were withheld by United Therapeutics to satisfy tax obligations upon vesting, a non-market disposition that does not represent an open-market sale. Following these transactions, the filing shows 19,046 shares held indirectly by the trust and 2,710 shares held directly, which includes 62 shares acquired earlier under the company’s employee stock purchase plan.
United Therapeutics Corp CFO and Treasurer James Edgemond exercised restricted stock units into 19,478 shares of common stock on
To cover tax obligations at vesting, 8,786 shares were withheld by United Therapeutics at a price of
United Therapeutics EVP & General Counsel Paul A. Mahon reported the vesting and conversion of restricted stock units into common shares. On March 15, 2026, 16,691 restricted stock units converted on a one-for-one basis into 16,691 shares of common stock, reflecting time- and performance-based awards granted in March 2023.
To cover tax obligations upon vesting, 8,363 of these shares were withheld by United Therapeutics at a reference price of $536.12 per share, rather than sold in the open market. After these transactions, Mahon directly owns 45,172 shares of United Therapeutics common stock.
United Therapeutics Chairperson and CEO Martine A. Rothblatt reported vesting and settlement of restricted stock units rather than open-market trades. On March 15, 2026, she exercised and converted a total of 69,579 restricted stock units into the same number of common shares on a one-for-one basis.
To cover tax obligations associated with these vestings, 29,196 common shares were withheld by United Therapeutics at $536.12 per share, a non-market tax-withholding disposition. After these transactions, Rothblatt directly held 40,513 shares of common stock, and the filing also shows additional indirect holdings through her spouse and various family trusts.
United Therapeutics director Jan Malcolm reported an open-market sale of company stock. On March 17, 2026, Malcolm sold 45 shares of Common Stock at an average price of $533.51 per share, and now directly holds 125 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan that Malcolm entered into on September 11, 2025, indicating the transaction was scheduled in advance rather than timed discretionarily.
UTHR files a Form 144 reporting the proposed sale of 45 shares of Common Stock (restricted stock) by an issuer-affiliated holder.
The filing lists multiple recent dispositions by the same holder: 50 shares sold on
UTHR filed Form 144 reporting sale transactions by Judy Olian. The filing lists two sales of Common shares:
UNITED THERAPEUTICS Corp director Judy D. Olian reported an open-market sale of company stock. On
After this sale, she directly holds 4,445 shares of UNITED THERAPEUTICS Common Stock. According to a footnote, this transaction was executed under a pre-arranged Rule 10b5-1 trading plan that she entered into on